# Synergism of Immunomodulation and Tumor Ablation

> **NCT03101475** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 22 (actual)

## Conditions studied

- Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** Durvalumab (MEDI4736)
- **DRUG:** Tremelimumab
- **RADIATION:** Sterotactic body radiation therapy (SBRT)
- **OTHER:** Radiofrequency ablation (RFA)

## Key facts

- **NCT ID:** NCT03101475
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-23
- **Primary completion:** 2021-03-03
- **Final completion:** 2022-02-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101475, "Synergism of Immunomodulation and Tumor Ablation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03101475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*